Sumitomo Pharma Co.,Ltd. [4506.T]
TOKYO, May 13 (Pulse News Wire) – Sumitomo Pharma CO.,LTD. (4506.T) reported revenue of ¥545 billion for the quarter ended March 2026, marking a 13.7% increase compared to the previous fiscal year.
Operating profit stood at ¥432 billion, up 145.4%. However, despite strong sales growth, operating income declined by 16.2% due to higher selling, general, and administrative expenses, as well as increased research and development costs. Key products such as Orgovyx and Gemtesa continued to drive revenue growth, contributing significantly to the overall performance. In North America, Orgovyx sales reached $2.099 billion, representing a 59% increase from the previous year.
Meanwhile, in Japan, Zepion and Zepion TRI contributed to the company's plans for increased revenue. Looking ahead, Sumitomo Pharma expects to maintain its focus on long-term investment while ensuring a robust financial foundation. The company anticipates further expansion in key markets through strategic promotional activities and enhanced product value communication. Additionally, Sumitomo Pharma highlighted the importance of leveraging regulatory changes to improve patient accessibility and awareness.
Despite facing challenges such as inflationary pressures and payer mix impacts, Sumitomo Pharma remains committed to achieving its financial targets and driving sustainable growth across its global operations.
🟢 Confidence: High AI-translated content.